REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer

Published on Sep 1, 2019in Radiotherapy and Oncology4.856
· DOI :10.1016/J.RADONC.2019.04.034
Petra Seibold27
Estimated H-index: 27
(DKFZ: German Cancer Research Center),
A Webb9
Estimated H-index: 9
(University of Leicester)
+ 125 AuthorsWilliam Li1
Estimated H-index: 1
(The Queen's Medical Center)
Sources
Abstract
Abstract Purpose REQUITE aimed to establish a resource for multi-national validation of models and biomarkers that predict risk of late toxicity following radiotherapy. The purpose of this article is to provide summary descriptive data. Methods An international, prospective cohort study recruited cancer patients in 26 hospitals in eight countries between April 2014 and March 2017. Target recruitment was 5300 patients. Eligible patients had breast, prostate or lung cancer and planned potentially curable radiotherapy. Radiotherapy was prescribed according to local regimens, but centres used standardised data collection forms. Pre-treatment blood samples were collected. Patients were followed for a minimum of 12 (lung) or 24 (breast/prostate) months and summary descriptive statistics were generated. Results The study recruited 2069 breast (99% of target), 1808 prostate (86%) and 561 lung (51%) cancer patients. The centralised, accessible database includes: physician- (47,025 forms) and patient- (54,901) reported outcomes; 11,563 breast photos; 17,107 DICOMs and 12,684 DVHs. Imputed genotype data are available for 4223 patients with European ancestry (1948 breast, 1728 prostate, 547 lung). Radiation-induced lymphocyte apoptosis (RILA) assay data are available for 1319 patients. DNA ( n  = 4409) and PAXgene tubes ( n  = 3039) are stored in the centralised biobank. Example prevalences of 2-year (1-year for lung) grade ≥2 CTCAE toxicities are 13% atrophy (breast), 3% rectal bleeding (prostate) and 27% dyspnoea (lung). Conclusion The comprehensive centralised database and linked biobank is a valuable resource for the radiotherapy community for validating predictive models and biomarkers. Patient summary Up to half of cancer patients undergo radiation therapy and irradiation of surrounding healthy tissue is unavoidable. Damage to healthy tissue can affect short- and long-term quality-of-life. Not all patients are equally sensitive to radiation “damage” but it is not possible at the moment to identify those who are. REQUITE was established with the aim of trying to understand more about how we could predict radiation sensitivity. The purpose of this paper is to provide an overview and summary of the data and material available. In the REQUITE study 4400 breast, prostate and lung cancer patients filled out questionnaires and donated blood. A large amount of data was collected in the same way. With all these data and samples a database and biobank were created that showed it is possible to collect this kind of information in a standardised way across countries. In the future, our database and linked biobank will be a resource for research and validation of clinical predictors and models of radiation sensitivity. REQUITE will also enable a better understanding of how many people suffer with radiotherapy toxicity.
Download
📖 Papers frequently viewed together
1 Citations
2018
1 Citations
20093.15BMC Cancer
10 Authors (James V. Lacey, ..., Patricia Hartge)
128 Citations
References38
Newest
#1Kyriaki Michailidou (University of Cambridge)H-Index: 53
#2Sara Lindström (Harvard University)H-Index: 60
Last. Douglas F. Easton (University of Cambridge)H-Index: 172
view all 359 authors...
Breast cancer risk is influenced by rare coding variants in susceptibility genes, such as BRCA1, and many common, mostly non-coding variants. However, much of the genetic contribution to breast cancer risk remains unknown. Here we report the results of a genome-wide association study of breast cancer in 122,977 cases and 105,974 controls of European ancestry and 14,068 cases and 13,104 controls of East Asian ancestry1. We identified 65 new loci that are associated with overall breast cancer risk...
555 CitationsSource
#1Christian Nicolaj Andreassen (Aarhus University Hospital)H-Index: 19
#2Barry S. Rosenstein (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 34
Last. Jan Alsner (Aarhus University Hospital)H-Index: 55
view all 44 authors...
Abstract Purpose Several small studies have indicated that the ATM rs1801516 SNP is associated with risk of normal tissue toxicity after radiotherapy. However, the findings have not been consistent. In order to test this SNP in a well-powered study, an individual patient data meta-analysis was carried out by the International Radiogenomics Consortium. Materials and methods The analysis included 5456 patients from 17 different cohorts. 2759 patients were given radiotherapy for breast cancer and 2...
53 CitationsSource
#1Jenny L DonovanH-Index: 106
#2Freddie C. HamdyH-Index: 94
Last. David E. Neal (University of Cambridge)H-Index: 111
view all 38 authors...
BackgroundRobust data on patient-reported outcome measures comparing treatments for clinically localized prostate cancer are lacking. We investigated the effects of active monitoring, radical prostatectomy, and radical radiotherapy with hormones on patient-reported outcomes. MethodsWe compared patient-reported outcomes among 1643 men in the Prostate Testing for Cancer and Treatment (ProtecT) trial who completed questionnaires before diagnosis, at 6 and 12 months after randomization, and annually...
554 CitationsSource
#1Athene Lane (UoB: University of Bristol)H-Index: 19
#2Chris Metcalfe (UoB: University of Bristol)H-Index: 61
Last. Jenny L Donovan (UoB: University of Bristol)H-Index: 106
view all 12 authors...
ProtecT Study group members are given in Appendix 1. Additional Supporting Information may be found in the online version of this article: Table S1 Symptoms and quality of life by occupational social class in men randomised in the ProtecT trial.
36 CitationsSource
#1Chamberlain Mbah (UGent: Ghent University)H-Index: 3
#2Hubert Thierens (UGent: Ghent University)H-Index: 61
Last. Kim De Ruyck (UGent: Ghent University)H-Index: 23
view all 9 authors...
Purpose To identify the main causes underlying the failure of prediction models for radiation therapy toxicity to replicate. Methods and Materials Data were used from two German cohorts, Individual Radiation Sensitivity (ISE) (n=418) and Mammary Carcinoma Risk Factor Investigation (MARIE) (n=409), of breast cancer patients with similar characteristics and radiation therapy treatments. The toxicity endpoint chosen was telangiectasia. The LASSO (least absolute shrinkage and selection operator) log...
6 CitationsSource
#1Sarah L. Kerns (URMC: University of Rochester Medical Center)H-Index: 27
#2Leila Dorling (University of Cambridge)H-Index: 13
Last. Catharine M L WestH-Index: 77
view all 28 authors...
Nearly 50% of cancer patients undergo radiotherapy. Late radiotherapy toxicity affects quality-of-life in long-term cancer survivors and risk of side-effects in a minority limits doses prescribed to the majority of patients. Development of a test predicting risk of toxicity could benefit many cancer patients. We aimed to meta-analyze individual level data from four genome-wide association studies from prostate cancer radiotherapy cohorts including 1564 men to identify genetic markers of toxicity...
47 CitationsSource
#1Anna Wilkins (ICR: Institute of Cancer Research)H-Index: 11
#2Helen Mossop (ICR: Institute of Cancer Research)H-Index: 10
Last. Emma Hall (ICR: Institute of Cancer Research)H-Index: 57
view all 23 authors...
Summary Background Patient-reported outcomes (PROs) might detect more toxic effects of radiotherapy than do clinician-reported outcomes. We did a quality of life (QoL) substudy to assess PROs up to 24 months after conventionally fractionated or hypofractionated radiotherapy in the Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy in Prostate Cancer (CHHiP) trial. Methods The CHHiP trial is a randomised, non-inferiority phase 3 trial done in 71 centres, of which 57 UK ho...
90 CitationsSource
#1David Azria (University of Montpellier)H-Index: 56
#2Olivier Riou (University of Montpellier)H-Index: 7
Last. Esat Mahmut OzsahinH-Index: 6
view all 21 authors...
article i nfo Background: Monocentric cohorts suggested that radiation-induced CD8 T-lymphocyte apoptosis (RILA) can predict late toxicity after curative intent radiotherapy (RT). We assessed the role of RILA as a predictor of breast fibrosis (bf+) after adjuvant breast RT in a prospective multicenter trial. Methods: A total of 502 breast-cancer patients (pts) treated by conservative surgery and adjuvant RT were re- cruitedatten centers. RILAwasassessedbeforeRTby flowcytometry.ImpactofRILAonbf+(...
61 CitationsSource
#1Gillian C. Barnett (Cambridge University Hospitals NHS Foundation Trust)H-Index: 27
#2Sarah L. Kerns (URMC: University of Rochester Medical Center)H-Index: 27
Last. Neil G. Burnet (University of Cambridge)H-Index: 50
view all 6 authors...
Abstract There is considerable variation in the level of toxicity patients experience for a given dose of radiotherapy, which is associated with differences in underlying individual normal tissue radiosensitivity. A number of syndromes have a large effect on clinical radiosensitivity, but these are rare. Among non-syndromic patients, variation is less extreme, but equivalent to a ±20% variation in dose. Thus, if individual normal tissue radiosensitivity could be measured, it should be possible t...
25 CitationsSource
#1Petra Seibold (DKFZ: German Cancer Research Center)H-Index: 27
#2Sabine Behrens (DKFZ: German Cancer Research Center)H-Index: 17
Last. Jenny Chang-Claude (DKFZ: German Cancer Research Center)H-Index: 124
view all 29 authors...
Purpose To identify single-nucleotide polymorphisms (SNPs) in oxidative stress–related genes associated with risk of late toxicities in breast cancer patients receiving radiation therapy. Methods and Materials Using a 2-stage design, 305 SNPs in 59 candidate genes were investigated in the discovery phase in 753 breast cancer patients from 2 prospective cohorts from Germany. The 10 most promising SNPs in 4 genes were evaluated in the replication phase in up to 1883 breast cancer patients from 6 c...
46 CitationsSource
Cited By15
Newest
#1Walter TinganelliH-Index: 9
#2Francesca Luoni (Technische Universität Darmstadt)H-Index: 2
Last. Marco Durante (Technische Universität Darmstadt)H-Index: 66
view all 0 authors...
Abstract null null Protection from cosmic radiation of crews of long-term space missions is now becoming an urgent requirement to allow a safe colonization of the moon and Mars. Epidemiology provides little help to quantify the risk, because the astronaut group is small and as yet mostly involved in low-Earth orbit mission, whilst the usual cohorts used for radiation protection on Earth (e.g. atomic bomb survivors) were exposed to a radiation quality substantially different from the energetic ch...
Source
#1Nicola Rares Franco (Ghent University Hospital)
#1Nicola Rares Franco (Ghent University Hospital)H-Index: 1
Last. Tiziana RancatiH-Index: 27
view all 43 authors...
AIM To identify the effect of single nucleotide polymorphism (SNP) interactions on the risk of toxicity following radiotherapy (RT) for prostate cancer (PCa) and propose a new method for polygenic risk score incorporating SNP-SNP interactions (PRSi). MATERIALS AND METHODS Analysis included the REQUITE PCa cohort that received external beam RT and was followed for 2 years. Late toxicity endpoints were: rectal bleeding, urinary frequency, haematuria, nocturia, decreased urinary stream. Among 43 li...
Source
#1Katalin LumniczkyH-Index: 18
#2Nathalie ImpensH-Index: 2
Last. Dörthe Schaue (UCLA: University of California, Los Angeles)H-Index: 23
view all 9 authors...
Ionizing radiation interacts with the immune system in many ways with a multiplicity that mirrors the complexity of the immune system itself: namely the need to maintain a delicate balance between different compartments, cells and soluble factors that work collectively to protect, maintain, and restore tissue function in the face of severe challenges including radiation damage. The cytotoxic effects of high dose radiation are less relevant after low dose exposure, where subtle quantitative and f...
1 CitationsSource
#1В. А. Вінніков (Academy of Medical Sciences, United Kingdom)
#2Т. В. Рубльова (Academy of Medical Sciences, United Kingdom)
Background. Among cancer patients receiving radiotherapy about 5–15 % may have adverse reactions in normal tissues and organs that limit their treatment in a full, originally scheduled regimen. The development of biomarkers and assays for radiation oncology allowing the prediction of patients’ normal tissue toxicity requires a lot of resourses, threfore its current status amd potential directions for future research have to be periodically analyzed and re-evaluated. Purpose – this review summari...
Source
Source
A search for effective methods for the assessment of patients’ individual response to radiation is one of the important tasks of clinical radiobiology. This review summarizes available data on the use of ex vivo cytogenetic markers, typically used for biodosimetry, for the prediction of individual clinical radiosensitivity (normal tissue toxicity, NTT) in cells of cancer patients undergoing therapeutic irradiation. In approximately 50% of the relevant reports, selected for the analysis in peer-r...
Source
#1David GillespieH-Index: 2
#2Connah KendrickH-Index: 6
Last. Moi Hoon Yap (MMU: Manchester Metropolitan University)H-Index: 23
view all 6 authors...
Prostate radiotherapy is a well established curative oncology modality, which in future will use Magnetic Resonance Imaging (MRI)-based radiotherapy for daily adaptive radiotherapy target definition. However the time needed to delineate the prostate from MRI data accurately is a time consuming process. Deep learning has been identified as a potential new technology for the delivery of precision radiotherapy in prostate cancer, where accurate prostate segmentation helps in cancer detection and th...
#1Tim Rattay (University of Leicester)H-Index: 9
#2Petra Seibold (DKFZ: German Cancer Research Center)H-Index: 27
Last. Sheryl GreenH-Index: 18
view all 119 authors...
Background: Acute skin toxicity is a common and usually transient side-effect of breast radiotherapy although, if sufficiently severe, it can affect breast cosmesis, aftercare costs and the patient's quality-of-life. The aim of this study was to develop predictive models for acute skin toxicity using published risk factors and externally validate the models in patients recruited into the prospective multi-center REQUITE (validating pREdictive models and biomarkers of radiotherapy toxicity to red...
1 CitationsSource
#1Michela Carlotta Massi (Polytechnic University of Milan)H-Index: 2
#2Francesca Gasperoni (Medical Research Council)H-Index: 1
Last. Tiziana RancatiH-Index: 27
view all 46 authors...
Background: REQUITE (validating pREdictive models and biomarkers of radiotherapy toxicity to reduce side effects and improve QUalITy of lifE in cancer survivors) is an international prospective cohort study. The purpose of this project was to analyse a cohort of patients recruited into REQUITE using a deep learning algorithm to identify patient-specific features associated with the development of toxicity, and test the approach by attempting to validate previously published genetic risk factors....
2 CitationsSource
Precision medicine and personalized treatment recommendations have become standard for systemic therapy decision-making in women with breast cancer. Until recently, however, such opportunities have been lacking for radiation related treatment decisions. Recent studies have explored the utility of using genomic signatures developed to make systemic therapy recommendations (e.g. Oncotype DX®, ProSigna®, IHC4-C) to guide recommendations for radiation as well. Emerging data suggests that these signa...
Source